RedHill Biopharma Ltd. announced that the U.S. FDA has accepted for review the New Drug Application (NDA) for Talicia (RHB-105)1 for H. pylori infection. The NDA for Talicia has also been granted Priority Review designation and was assigned a target Prescription Drug User Act (PDUFA) action date by the FDA of November 2, 2019.
Commercial launch of Talicia with RedHill’s existing U.S. sales force is planned shortly following potential FDA approval. If approved, Talicia would be eligible for a total of eight years of U.S. market exclusivity.
“The efficacy of current standard-of-care therapies for H. pylori bacterial infection continues to decline due to the high and steadily increasing prevalence of antibiotic-resistant strains. This public health concern is widely recognized by the U.S. government and other leading health agencies, including the World Health Organization, which classified H. pylori as a Group I carcinogen and highlighted the urgent need for new treatments for H. pylori eradication,” said Dror Ben-Asher, Chief Executive Officer of RedHill Biopharma. “The acceptance for review of the NDA for Talicia and the Priority Review designation are encouraging steps as we continue our intensive preparations for a potential U.S. commercial launch of Talicia as a new first-line, standard-of-care therapy for H. pylori. We continue to work closely with the FDA, with the aim of bringing this important new therapy to patients.”
Breaking News
FDA Accepts RedHill Biopharma’s NDA for Talicia
Commercial launch of H. pylori treatment is planned shortly following potential FDA approval
07.16.19
Related Breaking News
-
Financial Reports
Pfizer 1Q Revenues up 45% Driven by COVID Vax
Vaccine sales were $4.9 billion in the quarter, with BNT162b2 contributing $3.5 billion in global revenues.Kristin Brooks 05.05.21
-
Breaking News | Industry News
Multivac Unveils State of the Art Logistics Center
Invested $11.2M in facility at its U.S. headquarters in Kansas City.Tim Wright, Editor, Contract Pharma 05.05.21
-
Bio News | Breaking News | Collaborations & Alliances | Industry News
BioVaxys Inks Deal with CDMO BioElpida
Includes clinical-grade bioproduction and aseptic packaging for ovarian cancer vaccine candidate BXV-0918A.Tim Wright, Editor, Contract Pharma 05.05.21
-
Bio News | Breaking News | Industry News
Cellares Expands Cell Therapy Manufacturing Capabilities
Raises $82M to accelerate development of the Cell Shuttle scalable factory-in-a-box.Tim Wright, Editor, Contract Pharma 05.05.21
-
Bio News | Biologics, Proteins, Vaccines | Breaking News | Industry News
Clean Biologics Acquires Biodextris
To establish North American presence and expand activities with Biodextris’ complementary services.Tim Wright, Editor, Contract Pharma 05.05.21
-
Breaking News | Drug Development | Industry News
Exelixis Acquires GamaMabs Oncology Antibody Program
Gains AMHR2 franchise technology including all assets pertaining to GamaMabs’ monoclonal antibody drug product murlentamab.Kristin Brooks 05.04.21
-
Breaking News | Clinical Trials | CRO News | Information Technology
Syneos, Komodo Health Expand Data App Alliance
Leveraging Komodo’s Healthcare Map, Syneos aims to better analyze clinical, real-world, and commercial data.Kristin Brooks 05.04.21
-
Clinical Trials | Information Technology | Promotions & Moves
Clinical Ink Adds Executives
CCO Chris Crucitti, COO Brian Donahue, and VP Project Operations Bill Barrasso to manage eSource platforms.Kristin Brooks 05.04.21
-
Breaking News | cGMP Manufacture | Industry News | Information Technology
Autolomous to Expedite Digitization of Batch Verification
Will work to develop AutoloMATE-Assist, a digital batch verification technology for cell and gene therapies to alleviate paper based bottlenecks.Kristin Brooks 05.04.21
-
Biologics, Proteins, Vaccines | Breaking News | Industry News
Moderna to Increase Global Supply for COVID-19 Vaccine
Will supply up to 3 billion doses in 2022 and double supply from ex-U.S. supply chain.Tim Wright, Editor, Contract Pharma 05.03.21
-
Biologics, Proteins, Vaccines | Breaking News | Collaborations & Alliances | Fill/Finish | Industry News
Sanofi, Moderna Enter COVID-19 Vaccine Fill/Finish Manufacturing Deal
Sanofi will provide fill/finish services for up to 200 million doses of Moderna’s COVID-19 vaccine in the U.S. beginning in September 2021.Tim Wright, Editor, Contract Pharma 05.03.21
-
Bio News | Biologics, Proteins, Vaccines | Breaking News | Collaborations & Alliances | Industry News | R&D
Albumedix Extends Research Collaboration with Cobra Biologics
Collaboration investigates enhanced manufacturing of AAV and lentiviral vectors to improve quality and productivity for gene therapy and vaccine developers.Tim Wright, Editor, Contract Pharma 05.03.21
-
Bio News | Breaking News | Drug Development | Drug Discovery | Facilities | Industry News | Information Technology
AbCellera Breaks Ground on Global HQ in Vancouver
380,000 square feet of facilities envisioned as creative tech hub expected to be completed in 2023 and 2024.Tim Wright, Editor, Contract Pharma 05.03.21
-
Bio News | Breaking News | Facilities | Industry News
NuvOx Completes Construction of Expanded Manufacturing Facility
Will manufacture its lead product, NanO2, for clinical trials and commercial supply after FDA approval.Tim Wright, Editor, Contract Pharma 05.03.21
-
Bio News | Biologics, Proteins, Vaccines | Breaking News | Collaborations & Alliances | Drug Development | Industry News
CCRM and Amgen Partner to Advance Emerging Medical Innovations
New fund to support regenerative medicine discoveries with high potential impact for patients.Tim Wright, Editor, Contract Pharma 05.03.21
